Caribou’s off-the-shelf BCMA CAR-T receives RMAT designation for multiple myeloma

Caribou Biosciences, Inc. (Nasdaq: CRBU), headquartered in Berkeley, California, announced that the FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation to CB-011, an allogeneic anti-B-cell maturation antigen (BCMA) chimeric antigen receptor T-cell (CAR-T) therapy, for relapsed or refractory multiple myeloma (r/r MM). The designation adds to existing FDA Fast Track and Orphan Drug designations already held by CB-011 for the same indication, and confers eligibility for rolling and priority review and accelerated approval pathways, contingent on meeting relevant criteria at each stage.

The clinical data underpinning the RMAT decision derive from the ongoing CaMMouflage Phase I trial (NCT05722418), a multicenter, open-label, 3+3 dose-escalation study enrolling adults with r/r MM who have received three or more prior lines of therapy. As of a September 24, 2025 data cutoff, previously disclosed in November 2025, 48 patients had been treated across multiple dose levels and two lymphodepletion (LD) regimens. The 450×10⁶ CAR-T cell dose was selected as the recommended dose for expansion (RDE). Among the 12 BCMA-naïve patients treated, efficacy outcomes included a 92% (11/12) overall response rate (ORR), a ≥complete response (CR) rate of 75% (9/12), and minimal residual disease (MRD) negativity in 91% (10/11 evaluable) of patients. No cases of graft-versus-host disease, immune effector cell-associated enterocolitis, parkinsonism, or cranial nerve palsies were observed at any dose level. Treatment-emergent adverse events (TEAEs) occurring in ≥25% of patients treated under the selected LD regimen (N=35) included neutropenia (80%), anemia (60%), thrombocytopenia (49%), infections (49%), cytokine release syndrome (31%), and dizziness (31%).

The CaMMouflage trial has now moved into dose expansion, enrolling both BCMA-naïve and BCMA-exposed cohorts at the 450×10⁶ cell dose with cyclophosphamide 500 mg/m² and fludarabine 30 mg/m² daily for three days as the selected LD regimen. Caribou has indicated that initial dose expansion data, along with longer follow-up from dose escalation, are expected in 2026.

Research context

According to an investigator quoted in Caribou’s announcement, only approximately one in ten patients with multiple myeloma in the United States receives CAR-T therapy, a figure attributed to wait times and manufacturing limitations inherent to autologous approaches. CB-011’s allogeneic design — using donor-derived cells manufactured in advance — is intended to circumvent these logistical barriers.

The approved anti-BCMA CAR-T landscape in r/r MM currently includes two autologous products: idecabtagene vicleucel (ide-cel; Bristol Myers Squibb/2seventy bio) and ciltacabtagene autoleucel (cilta-cel; Janssen/Legend Biotech). Both carry FDA approvals in heavily pretreated r/r MM populations and have demonstrated deep response rates in their respective pivotal trials, but share the manufacturing constraints that Caribou’s off-the-shelf approach seeks to address. No allogeneic anti-BCMA CAR-T product has yet reached regulatory approval.

CB-011’s engineering distinguishes it from both approved autologous products and other allogeneic programs in development. According to Caribou, CB-011 is constructed using a beta-2 microglobulin (B2M) knockout combined with insertion of a B2M–HLA-E fusion protein — an immune-cloaking strategy designed to reduce host-mediated rejection of the allogeneic cells. The company states this makes CB-011 the first allogeneic CAR-T in the clinic to deploy this specific combination. Unlike autologous products such as ide-cel and cilta-cel, which rely on patient-derived T cells and are subject to manufacturing variability tied to individual patient immune status, CB-011 is manufactured from donor cells and stored for immediate deployment. The absence of graft-versus-host disease at any dose level in the CaMMouflage trial to date is a relevant safety signal for an allogeneic construct, though the patient numbers remain small and longer follow-up is needed.

The RMAT designation framework, established under the 21st Century Cures Act, applies to regenerative medicine therapies — including cell therapies — intended to treat serious conditions where preliminary clinical evidence indicates the potential to address unmet medical needs. The designation enables more intensive FDA engagement during development, including the possibility of rolling review submissions. For Caribou, the practical near-term implication is structured dialogue with the FDA on the clinical development path for CB-011, particularly as the program transitions from Phase I dose expansion toward a potential registrational strategy.